+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Extracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Focal segmental glomerulosclerosis (FSGS) is one of the most frequent and severe glomerular kidney disease with frequent progression to end-stage renal disease and a high rate of recurrence in renal transplantations. Due to intolerance or resistance to the current immunomodulatory treatments, the management of FSGS is a therapeutic challenge. Over the last few years, development in extracorporeal therapies has shown potential beneficial outcomes in drug-resistant and recurrent FSGS patients. Thus, this study reviews the current literature on the use of extracorporeal therapies, such as plasma exchange therapy, immunoadsorption, and low-density lipoprotein apheresis, for the treatment of FSGS in the pediatric population.

          Related collections

          Author and article information

          Blood Purif
          Blood Purification
          S. Karger AG
          September 2020
          19 February 2020
          : 49
          : 5
          : 513-523
          aDepartment of Pediatric Nephrology, Akron Children’s Hospital, Akron, Ohio, USA
          bDepartment of Internal Medicine and Pediatrics, University of Nebraska Medical Center, Omaha, Nebraska, USA
          cNortheast Ohio Medical University, Rootstown, Ohio, USA
          dAkron Nephrology Associates at Cleveland Clinic Akron General, Akron, Ohio, USA
          Author notes
          *Rupesh Raina, MD, FAAP, FACP, FASN, FNKF, Adult-Pediatric Kidney Disease/Hypertension, Department of Pediatric Nephrology, Akron Children’s Hospital, NEOMED and Department of Nephrology, Cleveland Clinic Akron General Medical Center, Akron, OH 44308 (USA), E-Mail and
          506277 Blood Purif 2020;49:513–523
          © 2020 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 1, Tables: 4, Pages: 11


          Comment on this article